Giorgi C, Marchi S, Simoes ICM, Ren Z, Morciano G, Perrone M, et al
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications originally developed for type 2 diabetes management, with some now FDA-approved for chronic weight management
The choice depends on individual priorities regarding convenience, bioavailability optimization, comfort with administration methods, and integration with existing health routines
Diet, evolution and aging--the pathophysiologic effects of the post-agricultural inversion of the potassium-to-sodium and base-to-chloride ratios in the human diet
BPC-157 is a synthetic pentadecapeptide studied extensively in preclinical in vitro and in vivo models for its cytoprotective, angiogenic, and anti-inflammatory properties
For side effects that alcohol can worsen, see GLP-1 side effects